Satellos CEO Joins PPMD Panel, Preps for Clinical Trial
Company Announcements

Satellos CEO Joins PPMD Panel, Preps for Clinical Trial

Satellos Bioscience (TSE:MSCL) has released an update.

Satellos Bioscience, a biotech firm focusing on muscle disease treatments, announced CEO Frank Gleeson will join a panel at the PPMD Annual Conference to discuss their progress, particularly their investment-backed oral drug candidate aimed at treating Duchenne muscular dystrophy. The company is preparing to submit a regulatory package for a Phase 1 clinical trial of SAT-3247, a novel drug designed to restore muscle regeneration. SAT-3247, which targets the underlying cause of muscle loss in degenerative diseases, is anticipated to enter human trials in the third quarter of 2024.

For further insights into TSE:MSCL stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Canadian Auto-Generated NewsdeskSatellos Bioscience to Attend Key Investor Conferences
TipRanks Canadian Auto-Generated NewsdeskSatellos Bioscience’s SAT-3247 Shows Promising DMD Treatment Results
TheFlySatellos Bioscience initiated with a Speculative Buy at Canaccord
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App